Close
Blog & Resources Camargo Blog February 15th, 2008

Metabolites: New Safety Testing Requirements—Impact on 505(b)(2)

For Valentine’s Day, FDA issued a new guidance on metabolite safety testing. Essentially, it outlines the non-clinical testing that may be required when the metabolism in humans produces significantly higher amounts of the same metabolites in the animal species where the toxicology was assessed.

As the guidance points out, recent advances in analytical technology have revealed instances where the tox data are potentially not indicative of the exposure in humans.

The impact on 505(b)(2) development plans is that in the interval since the approval of the RLD, metabolites may have been identified. These new or found-to-be-higher metabolites may need animal testing or, at least, justification why such testing is not needed



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights